The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...

Utilization of circulating tumor DNA (ctDNA) testing in biliary tract cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...

Tumor necrosis factor-α–converting enzyme (TACE; also known as ADAM17) is a proteolytic sheddase that is responsible for the cleavage of several membrane-bound molecules. We report that TACE cleaves ...

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer. Patients with unresectable hepatocellular ...

SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer. Adding durvalumab and bevacizumab to a well-known therapeutic ...

BTCRC-GI20-457: A phase II study of atezolizumab and bevacizumab in Child-Pugh B7 hepatocellular carcinoma (the AB7 Trial). Background: Limited treatment options are available for patients with ...

Comparative data on sequential transarterial chemoembolization (TACE) after stereotactic body radiation therapy (SBRT) in recurrent hepatocellular carcinoma (HCC) remain limited. This study aimed to ...

Please provide your email address to receive an email when new articles are posted on . Patients with hepatocellular carcinoma and clinically evident portal hypertension had significantly lower rates ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.